Physician profile
Jaclyn Diane Duvall
NPI 1740541473
$1,406,010.58
in general payments reported to CMS, 2019-2025
29 companies · $229K in 2025
The $229K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $199K · 2021: $366K · 2022: $281K · 2023: $168K · 2024: $142K · 2025: $229K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $268K · Consulting Fee: $102K · Honoraria: $97K · Travel and Lodging: $55K · Food and Beverage: $17K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $268,330.00 |
| Consulting Fee | $101,861.82 |
| Honoraria | $96,517.00 |
| Travel and Lodging | $55,442.92 |
| Food and Beverage | $16,723.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $544,264.45 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Lilly USA, LLC | $163,473.62 | 2019-2025 | Reyvow, Emgality, Kisunla |
| Allergan, INC. | $154,315.30 | 2019-2022 | |
| Lundbeck LLC | $151,490.91 | 2020-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $140,929.01 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $105,939.48 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $36,356.37 | 2019-2025 | Ajovy, Austedo Xr |
| H. Lundbeck A S | $36,278.72 | 2024-2025 | Vyepti |
| Impel Pharmaceuticals INC. | $31,786.28 | 2022-2023 | Trudhesa |
| Axsome Therapeutics, INC. | $21,779.95 | 2025 | Symbravo |
| Pfizer INC. | $5,760.24 | 2023-2025 | |
| Impel Pharmaceuticals LLC | $4,708.83 | 2024-2025 | Trudhesa, Trudhesa |
| Scilex Pharmaceuticals INC. | $3,000.62 | 2023-2025 | Ztlido |
| Supernus Pharmaceuticals, INC. | $1,746.98 | 2019-2022 | |
| Tonix Medicines, INC. | $1,682.94 | 2024 | Zembrace Symtouch |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $1,250.00 | 2022 | |
| Amgen INC. | $370.90 | 2019-2023 | Aimovig |
| Sunovion Pharmaceuticals INC. | $218.44 | 2019 | |
| Genzyme Corporation | $156.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $127.63 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $95.94 | 2023-2024 | Onzetra Xsail |
| Upsher-Smith Laboratories LLC | $90.49 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $40.91 | 2019-2025 | Brekiya |
| Collegium Pharmaceutical, INC. | $35.29 | 2022 | |
| Azurity Pharmaceuticals, INC. | $34.43 | 2023 | Horizant |
| Avanir Pharmaceuticals, INC. | $27.06 | 2019 | |
| Mallinckrodt Enterprises LLC | $22.09 | 2019 | |
| Biogen, INC. | $13.89 | 2019 | |
| Zyla Life Sciences, INC. | $12.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclyn Duvall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.